Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

This is a randomized, open-label, multi-center, international, Phase II study to assess the efficacy and safety of sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma. Patients will be randomized in a 1:1 ratio to one of the following arms: Arm A: initial treatment with durvalumab plus tremelimumab followed by treatment escalation with the addition of bevacizumab upon radiological progression or in the absence of objective response Arm B: up-front treatment with durvalumab, tremelimumab and bevacizumab Patients w

Trial Details

NCT ID
NCT05844046
Phase
PHASE2
Sponsor
Enrico De Toni
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • durvalumab, tremelimumab, bevacizumab
Locations (sample)
  • Munich, Germany|48.13743,11.57549
  • Munich, Germany|48.13743,11.57549
  • Würzburg, Germany|49.79391,9.95121

Key Eligibility Criteria

  • Age ≥18 years at the time of study entry
  • Confirmed HCC based on histopathological findings from tumor tissues.
  • Must not have received prior systemic therapy for HCC.
  • Not eligible for locoregional therapy for unresectable HCC. For patients who progressed after locoregional therapy for HCC, locoregional therapy mu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →